Altre lingue Takeda Pharmaceutical Company Limited London S.E.

Azioni

0A87

US8740602052

Mercato chiuso - London S.E. Altri mercati azionari 15:30:01 01/07/2024			Variaz. 5gg	Var. 1 gen.
13 ^USD	+0,90%		+0,71%	-8,61%

03/07	Blackstone vende il produttore di farmaci giapponese Alinamin a MBK Partners	RE
02/07	Il sistema FreedomEdge di Koru Medical Systems riceve l'approvazione normativa in Giappone	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Blackstone selling Japan drugmaker Alinamin to MBK Partners	03/07
Koru Medical Systems' FreedomEdge System Receives Regulatory Approval in Japan	02/07
KORU Medical Systems Receives Regulatory Clearance for FreedomEdge Infusion System in Japan	02/07
Codexis Sells Fabry, Pompe Disease Compounds to Crosswalk Therapeutics	01/07
Corza Medical Inc. completed the acquisition of TachoSil manufacturing operations in Linz, Austria. from Takeda Pharmaceutical Company Limited.	01/07
Takeda Pharmaceutical : Annual Securities Report (Part 1. Information on Takeda, IV. Information on the Company, 4. Corporate Governance)	28/06
Takeda Announces the Publication of its Annual Report on Form 20-F for FY2023	27/06
Takeda anuncia el nombramiento de nuevos cargos directivos	27/06
Takeda kündigt neue Besetzung der Direktorenposten an	27/06
Takeda annonce de nouvelles nominations de directeurs	27/06
TAKEDA PHARMACEUTICAL : Form 6 K	26/06
Takeda Pharmaceutical : Announces New Assignments of Directors Form 6 K	26/06
Takeda Announces New Assignments of Directors	26/06
US CDC alerts healthcare providers of increase in dengue cases	25/06
Takeda's Cancer Drug Gets European Commission Approval	25/06
Hutchmed China notes Takeda obtains EU approval for Fruzaqla	24/06
Takeda's Organ Transplant Infection Treatment Approved by Japan Regulators	24/06
Hutchmed (China), Takeda Secure EU Approval for Colorectal Cancer Treatment	24/06
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies	24/06
Takeda Announces Approval of LIVTENCITY® by the Japanese Ministry of Health, Labour and Welfare	24/06

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Takeda Pharmaceutical Company Limited London S.E.

Azioni

0A87

US8740602052

Altre lingue

Filtri